Abramson Cancer Center at Penn Medicine — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Abramson Cancer Center at Penn Medicine appears in 154 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials154

Recruiting shown22

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)NCT07454499 · lead sponsor · 2026-05-13

A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical TrialsNCT07040891 · lead sponsor · 2026-02-01

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer SurvivorshipNCT07655934 · lead sponsor · 2026-01-20

Safe and Explainable AINCT06694181 · lead sponsor · 2025-11-29

Telehealth Collaborative Care Model (CoCM) in Lung CancerNCT07102147 · lead sponsor · 2025-08-18

Hypofractionated WPPT With HDR BoostNCT06591819 · lead sponsor · 2025-01-15

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast CancerNCT06551116 · lead sponsor · 2024-10-10

Integrating Telehealth to Advance Lung Cancer ScreeningNCT06638554 · lead sponsor · 2024-07-09

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulESNCT05968898 · lead sponsor · 2024-01-09

Prostate Tissue BioBankNCT06659614 · lead sponsor · 2024-01-01

FES BPET-DBT in Newly Diagnosed Breast CancerNCT05659797 · lead sponsor · 2023-10-02

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based TherapyNCT04691817 · lead sponsor · 2023-07-25

FTT PET/CT in Metastatic Prostate CancerNCT05242744 · lead sponsor · 2023-03-01

Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)NCT03760575 · lead sponsor · 2023-01-10

Role of the Immune Environment in Response to Therapy in Breast CancerNCT05396612 · lead sponsor · 2022-10-03

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast CancerNCT04523857 · lead sponsor · 2021-11-01

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerNCT04841148 · lead sponsor · 2021-06-01

CTNNA1 Familial Expansion StudyNCT05126290 · lead sponsor · 2021-03-16

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab MaintenanceNCT04332367 · lead sponsor · 2020-08-01

[18F] F-GLN by PET/CT in Breast CancerNCT03863457 · lead sponsor · 2019-04-05

Safety Trial of Antimicrobial Therapy and Precision Radiation Therapy in Patients With Oligoprogressive Non-small Cell Lung CancerNCT03546829 · lead sponsor · 2019-03-05

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast CancerNCT02732171 · lead sponsor · 2016-04-01

Pilot Study of TumorGlow for Intraoperative Molecular Imaging of Sarcoma Metastases to the Lungs in Pediatric PatientsNCT07658768 · lead sponsor · 2026-09-01

NOT_YET_RECRUITING

Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in OncologyNCT06955468 · lead sponsor · 2025-07-21

Increasing Screening for Cancer Using EHR-Nudges ReplicationNCT06995703 · lead sponsor · 2025-06-02

Effects of Immune Checkpoint Inhibitors on Coronary MicrovasculatureNCT06332131 · lead sponsor · 2025-01-15

ACTIVE_NOT_RECRUITING

Community Support Program for Lung Cancer Screening Volume IINCT06628167 · lead sponsor · 2024-10-01

Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast CancerNCT06019988 · lead sponsor · 2024-03-11

ACTIVE_NOT_RECRUITING

Hypertension and Arrhythmias in CLL Patients Treated With BTK InhibitorsNCT06211413 · lead sponsor · 2024-02-07

ENROLLING_BY_INVITATION

Increasing Screening for Cancer Using EHR-NudgesNCT06177795 · lead sponsor · 2023-12-18

A Patient-Oriented Research Mentoring Program in Tobacco Dependence and Implementation Science ResearchNCT05852860 · lead sponsor · 2023-12-01

ENROLLING_BY_INVITATION

Increasing Adherence to Lung Cancer ScreeningNCT05832008 · lead sponsor · 2023-10-18

Improving Utilization of Supplemental Breast MRI Screening for Women With Extremely Dense BreastsNCT05787249 · lead sponsor · 2023-10-04

Behavioral Relaxation Approaches for Insomnia in Lung Cancer PatientsNCT04318249 · lead sponsor · 2023-09-30

Lung Cancer Screening Eligibility AssessmentNCT06133816 · lead sponsor · 2023-07-31

ChatBot and Activity Monitoring in Patients Undergoing ChemoradiotherapyNCT05318027 · lead sponsor · 2023-05-22

ACTIVE_NOT_RECRUITING

Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung CancerNCT05790460 · lead sponsor · 2023-05-08

Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer PredispositionNCT05721326 · lead sponsor · 2023-05-01

The Association Between CBT-I Dose, Sleep Duration, and Fatigue in Breast Cancer PatientsNCT05226078 · lead sponsor · 2023-03-01

ACTIVE_NOT_RECRUITING

Community Support Program for Lung Cancer ScreeningNCT06207435 · lead sponsor · 2023-02-10

Project PLUS Lung Cancer Screening PromotionNCT05937399 · lead sponsor · 2022-12-02

RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors (ALLSTAR)NCT05176756 · lead sponsor · 2022-04-14

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate CancerNCT05096338 · lead sponsor · 2021-10-27

ACTIVE_NOT_RECRUITING

Breast Cancer Outreach Among Primary Care PatientsNCT05089903 · lead sponsor · 2021-10-25

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Breast CancerNCT05078190 · lead sponsor · 2021-10-21

ACTIVE_NOT_RECRUITING

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense BreastsNCT04854304 · lead sponsor · 2021-09-23

ACTIVE_NOT_RECRUITING

Telehealth Weight Loss Program for Breast Cancer SurvivorsNCT04855552 · lead sponsor · 2021-07-19

ACTIVE_NOT_RECRUITING

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer ScreeningNCT04798664 · lead sponsor · 2021-05-17

BAPS in Botswana: The Thotloetso TrialNCT04532970 · lead sponsor · 2021-05-06

Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerNCT04735068 · lead sponsor · 2021-04-09

Pilot Study of an NTproBNP Guided Strategy of CardioprotectionNCT04737265 · lead sponsor · 2021-03-18

Implementation Strategies for Monitoring Adherence in Real TimeNCT04347161 · lead sponsor · 2021-02-22

ACTIVE_NOT_RECRUITING

India HIV-CervCa ProjectNCT07167069 · lead sponsor · 2021-02-09

Functional Lung Imaging With DECT and 4DCTNCT04702607 · lead sponsor · 2021-01-02

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade TherapyNCT04454528 · lead sponsor · 2020-12-07

ACTIVE_NOT_RECRUITING

PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI CancersNCT04616768 · lead sponsor · 2020-11-19

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair DefectsNCT04288687 · lead sponsor · 2020-10-19

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerNCT03685331 · lead sponsor · 2020-10-15

The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer PatientsNCT06604247 · lead sponsor · 2020-09-30

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation TherapyNCT04305613 · lead sponsor · 2020-09-14

ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

33 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Abramson Cancer Center at Penn Medicine as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

paclitaxel4

cisplatin3

pembrolizumab3

carboplatin2

etoposide2

hydroxychloroquine2

palbociclib2

abemaciclib1

paclitaxel RxCUI 56946 · Lead sponsor in 4 linked trial(s) · 1 currently recruiting 4 trials cisplatin RxCUI 2555 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 3 linked trial(s) · 1 currently recruiting 3 trials carboplatin RxCUI 40048 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials etoposide RxCUI 4179 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials hydroxychloroquine RxCUI 5521 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials palbociclib RxCUI 1601374 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials abemaciclib RxCUI 1946825 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial Abraxane RxCUI 589511 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial atezolizumab RxCUI 1792776 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial avelumab RxCUI 1875534 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial carvedilol RxCUI 20352 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial everolimus RxCUI 141704 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial exemestane RxCUI 258494 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gabapentin RxCUI 25480 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gedatolisib RxCUI 2747771 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial indocyanine green RxCUI 5775 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ipilimumab RxCUI 1094833 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nelfinavir RxCUI 134527 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial nelfinavir mesylate RxCUI 266565 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor152

collaborator2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.